Patents by Inventor Lourens Jan Dirk Zaneveld

Lourens Jan Dirk Zaneveld has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6706276
    Abstract: Antimicrobial and contraceptive compositions and methods which prevent and/or reduce the risk of transmission of sexually transmitted diseases through sexual activity as well as prevent and/or reduce the risk of pregnancy are provided.
    Type: Grant
    Filed: March 6, 2001
    Date of Patent: March 16, 2004
    Assignee: Rush-Presbyterian-St. Luke's Medical Center
    Inventors: Sanjay Garg, Lourens Jan Dirk Zaneveld, Robert Anthony Anderson, Jr., Donald Paul Waller
  • Publication number: 20040009223
    Abstract: Antimicrobial and contraceptive compositions and methods which prevent and/or reduce the risk of transmission of sexually transmitted diseases through sexual activity as well as prevent and/or reduce the risk of pregnancy are provided.
    Type: Application
    Filed: March 6, 2001
    Publication date: January 15, 2004
    Applicant: RUSH-PRESBYTERIAN-ST. LUKE'S MEDICAL CENTER
    Inventors: Sanjay Garg, Lourens Jan Dirk Zaneveld, Robert Anthony Anderson, Donald Paul Waller
  • Patent number: 6537538
    Abstract: A method for preventing, inhibiting, or treating vaginitis or bacterial vaginosis using polystyrene sulfonate is provided. The polystyrene sulfonate used in the present invention inhibits Trichomonas (a flagellate protozoon), Gardnerella, and other vaginitis/vaginosis-causing bacteria. The method of this invention generally comprises the application of an effective amount of an inhibitory agent into the vagina of a female in need of prevention, inhibition, and/or treatment of vaginitis and/or bacterial vaginosis. Preferably the polystyrene sulfonate in contained in an aqueous based composition, more preferably in an aqueous based composition buffered to a pH of about 3.5 to about 7.5, and even more preferably in an aqueous based composition buffered to a pH of about 3.5 to about 5.
    Type: Grant
    Filed: December 18, 2000
    Date of Patent: March 25, 2003
    Assignee: Rush-Presbyterian-St. Luke's Medical Center
    Inventors: Lourens Jan Dirk Zaneveld, Robert Anthony Anderson, Jr.
  • Publication number: 20020114776
    Abstract: A method for preventing, inhibiting, or treating vaginitis or bacterial vaginosis using polystyrene sulfonate is provided. The polystyrene sulfonate used in the present invention inhibits Trichomonas (a flagellate protozoon), Gardnerella, and other vaginitis/vaginosis-causing bacteria. The method of this invention generally comprises the application of an effective amount of an inhibitory agent into the vagina of a female in need of prevention, inhibition, and/or treatment of vaginitis and/or bacterial vaginosis. Preferably the polystyrene sulfonate in contained in an aqueous based composition, more preferably in an aqueous based composition buffered to a pH of about 3.5 to about 7.5, and even more preferably in an aqueous based composition buffered to a pH of about 3.5 to about 5.
    Type: Application
    Filed: December 18, 2000
    Publication date: August 22, 2002
    Applicant: Rush-Presbyterian-St. Luke's Medical Center
    Inventors: Lourens Jan Dirk Zaneveld, Robert Anthony Anderson
  • Patent number: 6239182
    Abstract: A method for the reduction in the risk of transmitting a sexually transmitted disease—especially HIV and/or HSV—during sexual activity is provided. This method generally comprises the application of an effective amount of an inhibitory agent, preferably as a topical formulation, to the area or areas of sexual contact prior to engaging in sexual activity. Inhibitory agents which are useful in the present invention include, for example, phosphorylated hesperidins, sulfonated hesperidins, polystyrene sulfonates, substituted benzenesulfonic acid formaldehyde co-polymers, H2SO4-modified mandelic acids, and the like. This method can be used by heterosexuals, homosexuals, and/or bisexuals engaged in a wide variety of sexual activities. In addition to anti-STD activity, these agents may also act as vaginal contraceptives; moreover, they generally have fewer side effects than conventional vaginal contraceptives (e.g., nonoxynol-9).
    Type: Grant
    Filed: February 18, 1999
    Date of Patent: May 29, 2001
    Assignee: Rush-Presbyterian-St. Lukes Medical Center
    Inventors: Lourens Jan Dirk Zaneveld, Robert Anthony Anderson, Jr., Xiao Hui Diao, Paul Robert Young, Jr., Donald Paul Waller, Sanjay Garg, Calvin J. Chany, II
  • Patent number: 6028115
    Abstract: A method for the reduction in the risk of transmitting a sexually transmitted disease--especially HIV and/or HSV--during sexual activity is provided. This method generally comprises the application of an effective amount of an inhibitory agent, preferably as a topical formulation, to the area or areas of sexual contact prior to engaging in sexual activity. Inhibitory agents which are useful in the present invention include, for example, phosphorylated hesperidins, sulfonated hesperidins, polystyrene sulfonates, substituted benzenesulfonic acid formaldehyde co-polymers, H.sub.2 SO.sub.4 -modified mandelic acids, and the like. This method can be used by heterosexuals, homosexuals, and/or bisexuals engaged in a wide variety of sexual activities. In addition to anti-STD activity, these agents may also act as vaginal contraceptives; moreover, they generally have fewer side effects than conventional vaginal contraceptives (e.g., nonoxynol-9).
    Type: Grant
    Filed: February 3, 1999
    Date of Patent: February 22, 2000
    Assignee: Rush-Presbyterian-St. Luke's Medical Center
    Inventors: Lourens Jan Dirk Zaneveld, Robert Anthony Anderson, Jr., Xiao Hui Diao, Paul Robert Young, Jr., Donald Paul Waller, Sanjay Garg, Calvin J. Chany, II
  • Patent number: 5932619
    Abstract: A method for the reduction in the risk of transmitting a sexually transmitted disease--especially HIV and/or HSV--during sexual activity is provided. This method generally comprises the application of an effective amount of an inhibitory agent, preferably as a topical formulation, to the area or areas of sexual contact prior to engaging in sexual activity. Inhibitory agents which are useful in the present invention include, for example, phosphorylated hesperidins, sulfonated hesperidins, polystyrene sulfonates, substituted benzenesulfonic acid formaldehyde co-polymers, H.sub.2 SO.sub.4 -modified mandelic acids, and the like. This method can be used by heterosexuals, homosexuals, and/or bisexuals engaged in a wide variety of sexual activities. In addition to anti-STD activity, these agents may also act as vaginal contraceptives; moreover, they generally have fewer side effects than conventional vaginal contraceptives (e.g., nonoxynol-9).
    Type: Grant
    Filed: November 7, 1997
    Date of Patent: August 3, 1999
    Assignee: Rush-Presbyterian, St. Luke's Medical Center
    Inventors: Lourens Jan Dirk Zaneveld, Robert Anthony Anderson, Jr., Xiao Hui Diao, Paul Robert Young, Jr., Donald Paul Waller, Sanjay Garg, Calvin J. Chany, II, Darrick S. H. L. Kim
  • Patent number: 5925621
    Abstract: A method for the reduction in the risk of transmitting a sexually transmitted disease--especially HIV and/or HSV--during sexual activity is provided. This method generally comprises the application of an effective amount of an inhibitory agent, preferably as a topical formulation, to the area or areas of sexual contact prior to engaging in sexual activity. Inhibitory agents which are useful in the present invention include, for example, phosphorylated hesperidins, sulfonated hesperidins, polystyrene sulfonates, substituted benzenesulfonic acid formaldehyde co-polymers, H.sub.2 SO.sub.4 -modified mandelic acids, and the like. This method can be used by heterosexuals, homosexuals, and/or bisexuals engaged in a wide variety of sexual activities. In addition to anti-STD activity, these agents may also act as vaginal contraceptives; moreover, they generally have fewer side effects than conventional vaginal contraceptives (e.g., nonoxynol-9).
    Type: Grant
    Filed: October 14, 1997
    Date of Patent: July 20, 1999
    Assignee: Rush-Presbyterian, St. Luke's Medical Center
    Inventors: Lourens Jan Dirk Zaneveld, Robert Anthony Anderson, Jr., Xiao Hui Diao, Paul Robert Young, Jr., Donald Paul Waller, Sanjay Garg, Calvin J. Chany, II